5 Key Takeaways

• 1

  Aflibercept 8 mg achieved noninferior vision gains with fewer injections than 2 mg in treatment-naïve patients with RVO.

• 2

  The QUASAR trial demonstrated consistent outcomes across BRVO, CRVO, and HRVO subtypes at the 36-week mark.

• 3

  Patients receiving aflibercept 8 mg required an average of 6.1 injections, compared to 8.8 injections for the 2 mg group.

• 4

  Approximately 70% of patients in the 8 mg group could extend treatment intervals to every 12 weeks by week 36.

• 5

  Aflibercept 8 mg was well tolerated, showing no new safety concerns and maintaining the established safety profile of 2 mg.